Last reviewed · How we verify

Paclitaxel, Docetaxel, Irinotecan

Shanghai Hengrui Pharmaceutical Co., Ltd. · Phase 3 active Small molecule

Paclitaxel, Docetaxel, Irinotecan is a Microtubule inhibitor Small molecule drug developed by Shanghai Hengrui Pharmaceutical Co., Ltd.. It is currently in Phase 3 development for Non-small cell lung cancer, Ovarian cancer, Pancreatic cancer.

Paclitaxel, Docetaxel, and Irinotecan are microtubule inhibitors that work by stabilizing microtubules, thereby inhibiting cell division.

Paclitaxel, Docetaxel, and Irinotecan are microtubule inhibitors that work by stabilizing microtubules, thereby inhibiting cell division. Used for Non-small cell lung cancer, Ovarian cancer, Pancreatic cancer.

At a glance

Generic namePaclitaxel, Docetaxel, Irinotecan
SponsorShanghai Hengrui Pharmaceutical Co., Ltd.
Drug classMicrotubule inhibitor
TargetMicrotubules
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

This mechanism prevents cancer cells from dividing and growing, ultimately leading to cell death. Paclitaxel and Docetaxel are taxanes, which are a class of microtubule stabilizing agents. Irinotecan is a topoisomerase I inhibitor, but it also has microtubule stabilizing properties.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Paclitaxel, Docetaxel, Irinotecan

What is Paclitaxel, Docetaxel, Irinotecan?

Paclitaxel, Docetaxel, Irinotecan is a Microtubule inhibitor drug developed by Shanghai Hengrui Pharmaceutical Co., Ltd., indicated for Non-small cell lung cancer, Ovarian cancer, Pancreatic cancer.

How does Paclitaxel, Docetaxel, Irinotecan work?

Paclitaxel, Docetaxel, and Irinotecan are microtubule inhibitors that work by stabilizing microtubules, thereby inhibiting cell division.

What is Paclitaxel, Docetaxel, Irinotecan used for?

Paclitaxel, Docetaxel, Irinotecan is indicated for Non-small cell lung cancer, Ovarian cancer, Pancreatic cancer, Breast cancer.

Who makes Paclitaxel, Docetaxel, Irinotecan?

Paclitaxel, Docetaxel, Irinotecan is developed by Shanghai Hengrui Pharmaceutical Co., Ltd. (see full Shanghai Hengrui Pharmaceutical Co., Ltd. pipeline at /company/shanghai-hengrui-pharmaceutical-co-ltd).

What drug class is Paclitaxel, Docetaxel, Irinotecan in?

Paclitaxel, Docetaxel, Irinotecan belongs to the Microtubule inhibitor class. See all Microtubule inhibitor drugs at /class/microtubule-inhibitor.

What development phase is Paclitaxel, Docetaxel, Irinotecan in?

Paclitaxel, Docetaxel, Irinotecan is in Phase 3.

What are the side effects of Paclitaxel, Docetaxel, Irinotecan?

Common side effects of Paclitaxel, Docetaxel, Irinotecan include Neutropenia, Anemia, Thrombocytopenia, Diarrhea, Fatigue.

What does Paclitaxel, Docetaxel, Irinotecan target?

Paclitaxel, Docetaxel, Irinotecan targets Microtubules and is a Microtubule inhibitor.

Related